Latest News of YMAB
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
Investing in stocks carries risks, but finding a high-quality company like Y-mAbs Therapeutics (YMAB) can yield significant returns. Despite recent fluctuations, its long-term performance and revenue ...
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners' Top Holdings Now?
Caligan Partners, a significant specialty hedge fund, focuses on healthcare investments in the US. They engage in activist strategies, pushing for strategic changes in companies to enhance shareholder...
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Despite losing money, shareholders can profit if they buy a good business at the right price. Y-mAbs Therapeutics has a reassuringly long cash runway of about 4.3 years, showing progress with reduced ...